PMID- 30793355
OWN - NLM
STAT- MEDLINE
DCOM- 20191224
LR  - 20191224
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 44
IP  - 5
DP  - 2019 Jul
TI  - Efficacy of a combination of diluted calcium hydroxylapatite-based filler and an 
      energy-based device for the treatment of facial atrophic acne scars.
PG  - e171-e176
LID - 10.1111/ced.13952 [doi]
AB  - BACKGROUND: Treatment options for atrophic acne scars include the use of various 
      energy-based devices (EBDs) and dermal fillers. AIM: To evaluate the level of 
      improvement and safety of four treatments for atrophic acne scars used in our 
      centre. METHODS: We reviewed the medical records of all patients with acne scars 
      treated between 2013 and 2016 with one of four treatments: ablative fractional 
      CO(2) laser (FACL), a radiofrequency (RF) bipolar device, a 1540 nm nonablative 
      fractional laser (NAFL) and injection of diluted calcium hydroxylapatite (CaHA). 
      The EBDs were used either as monotherapy or in combination with diluted CaHA. The 
      aesthetic improvement achieved following the various treatments was evaluated by 
      the patients and by two independent dermatologists who were not involved in the 
      treatments. The patients also rated their satisfaction with the treatment, 
      recorded the number of days of downtime (including time to full recovery and time 
      for resolution of redness) and reported any adverse effects (AEs). RESULTS: In 
      total, 352 patients (mean +/- SD age 28.7 +/- 8.7 years; 65.6% women, 34.4% men) were 
      treated for acne scars. The integrated mean Global Assessment Scale by both 
      dermatologists and patients were highest for the combined CaHA-FACL treatment at 
      separate sessions (injection in one session; laser treatment in another) 
      (P < 0.001). However, patients treated with FACL reported more AEs and longer 
      downtime and duration of erythema. CONCLUSION: The combination of a diluted 
      CaHA-based filler injection followed by FACL in separate treatment sessions 
      yielded better aesthetic improvement compared with the other tested treatments.
CI  - (c) 2019 British Association of Dermatologists.
FAU - Koren, A
AU  - Koren A
AUID- ORCID: 0000-0001-8667-9330
AD  - Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
FAU - Isman, G
AU  - Isman G
AD  - Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
FAU - Cohen, S
AU  - Cohen S
AD  - Department of Plastic and Reconstructive Surgery, Assaf Harofeh Medical Center, 
      Zerifin, Israel.
FAU - Bar Ilan, E
AU  - Bar Ilan E
AD  - Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
FAU - Salameh, F
AU  - Salameh F
AD  - Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
FAU - Sprecher, E
AU  - Sprecher E
AUID- ORCID: 0000-0002-4093-1032
AD  - Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
AD  - Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Artzi, O
AU  - Artzi O
AUID- ORCID: 0000-0003-1391-5843
AD  - Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20190329
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Dermal Fillers)
RN  - 91D9GV0Z28 (Durapatite)
SB  - IM
MH  - Acne Vulgaris/*complications
MH  - Adult
MH  - Cicatrix/etiology/*therapy
MH  - Combined Modality Therapy
MH  - Dermal Fillers/*therapeutic use
MH  - Durapatite/*therapeutic use
MH  - Face
MH  - Female
MH  - Humans
MH  - Laser Therapy/*methods
MH  - Lasers, Gas/therapeutic use
MH  - Male
MH  - Radiofrequency Therapy/*methods
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2019/02/23 06:00
MHDA- 2019/12/25 06:00
CRDT- 2019/02/23 06:00
PHST- 2019/02/19 00:00 [accepted]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/12/25 06:00 [medline]
PHST- 2019/02/23 06:00 [entrez]
AID - 10.1111/ced.13952 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2019 Jul;44(5):e171-e176. doi: 10.1111/ced.13952. Epub 2019 
      Mar 29.